Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology

American Journal of Transplantation

Volumn 16, Issue 6, 2016, Pages 1726-1738

  Burghuber, C K ^a,b   Kwun, J ^a,c   Page, E J ^a   Manook, M ^c   Gibby, A C ^a   Leopardi, F V ^a,c   Song, M ^a,c   Farris, A B ^d   Hong, J J ^d,e,f   Villinger, F ^d,e   Adams, A B ^a   Iwakoshi, N N ^a   Knechtle, S J ^a,c  

^a EMORY UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

^f Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD20 ANTIGEN; CD27 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G ANTIBODY; INDUCIBLE T CELL COSTIMULATOR; KI 67 ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NATURAL KILLER CELL RECEPTOR NKG2A; PROGRAMMED DEATH 1 LIGAND 1; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOIMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY MEDIATED REJECTION; ANTIBODY RESPONSE; ARTERY INTIMA PROLIFERATION; ARTICLE; AUTOPSY; BIOLOGY; CAPILLARITIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; COLOR DOPPLER FLOWMETRY; COMPLEMENT COMPONENT C4D DEPOSITION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DESENSITIZATION; DONOR SPECIFIC ANTIBODY RESPONSE; ELECTRON MICROSCOPY; FIBRIN DEPOSITION; GERMINAL CENTER; GLOMERULITIS; GLOMERULOPATHY; GRAFT SURVIVAL; HELPER CELL; HISTOLOGY; HUMAN; HUMORAL IMMUNITY; HYPERACUTE GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; KIDNEY ALLOGRAFT REJECTION; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LYMPH NODE FOLLICULAR HELPER T CELL; MALE; MEMORY CELL; MONONUCLEAR CELL; NEUTROPHIL; NONHUMAN; PERITUBULAR CAPILLARITIS; POSTOPERATIVE COMPLICATION; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; SENSITIZATION; SKIN GRAFT; T CELL DEPLETION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84978795764     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13688     Document Type: Article

References (42)

1. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: Kidney. Am J Transplant 2013; 14: 1–44.
2. Annual Report 2013. Eurotransplant International Foundation. 2014 May 17 [cited 2015 Oct 24]. Available from: http://www.eurotransplant.org.
3. Vo AA, Sinha A, Haas M, et al. Factors predicting risk for antibody-mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation 2015; 99: 1423–1430.
4. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS. Calculated PRA: Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011; 11: 719–724.
5. Israni AK, Salkowski N, Gustafson S, et al. New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. J Am Soc Nephrol 2014; 25: 1842–1848.
6. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318–326.
7. Sharif A, Kraus ES, Zachary AA, et al. Histologic phenotype on 1-year posttransplantation biopsy and allograft survival in HLA-incompatible kidney transplants. Transplantation 2014; 97: 541–547.
8. Bagnasco SM, Zachary AA, Racusen LC, et al. Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients. Transplantation 2014; 97: 440–445.
9. Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: A multicenter study. Am J Transplant 2014; 14: 1573–1580.
10. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76–85.
11. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684–2694.
12. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA Antibody-Mediated Rejection Workshop. Am J Transplant 2011; 11: 896–906.
13. Page EK, Page AJ, Kwun J, et al. Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. Am J Transplant 2012; 12: 2395–2405.
14. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272–283.
15. Welch BL. The generalisation of student's problems when several different population variances are involved. Biometrika 1947; 34: 28–35.
16. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1–Correlation within subjects. BMJ 1995; 310: 446.
17. Colvin RB, Cohen AH, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection: Reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997; 8: 1930–1941.
18. Mavilio D, Benjamin J, Kim D, et al. Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood 2005; 106: 1718–1725.
19. Autissier P, Soulas C, Burdo TH, Williams KC. Immunophenotyping of lymphocyte, monocyte and dendritic cell subsets in normal rhesus macaques by 12-color flow cytometry: Clarification on DC heterogeneity. J Immunol Methods 2010; 360: 119–128.
20. Pereira LE, Johnson RP, Ansari AA. Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. Cell Immunol 2008; 254: 10–19.
21. Anglicheau D, Loupy A, Suberbielle C, et al. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant 2007; 7: 1185–1192.
22. Hellemans R, Hazzan M, Durand D, et al. Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: Five-year follow-up of a randomized study. Am J Transplant 2015; 15: 1923–1932.
23. Brokhof MM, Sollinger HW, Hager DR, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation 2014; 97: 612–617.
24. van der Windt DJ, Smetanka C, Macedo C, et al. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys. Am J Transplant 2010; 10: 773–783.
25. Shimizu A, Meehan SM, Kozlowski T, et al. Acute humoral xenograft rejection: Destruction of the microvascular capillary endothelium in pig-to-nonhuman primate renal grafts. Lab Invest 2000; 80: 815–830.
26. Shimizu A, Yamada K, Robson SC, Sachs DH, Colvin RB. Pathologic characteristics of transplanted kidney xenografts. J Am Soc Nephrol 2012; 23: 225–235.
27. Satoskar AA, Pelletier R, Adams P, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010; 10: 1804–1811.
28. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517–1523.
29. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550–555.
30. Vo AA, Sinha A, Haas M, et al. Factors predicting risk for antibody-mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation 2015; 99: 1423–1430.
31. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: Lessons from pathology. Clin J Am Soc Nephrol 2006; 1: 415–420.
32. Randhawa PS, Tsamandas AC, Magnone M, et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol 1996; 20: 306–312.
33. Young BA, Marsh CL, Alpers CE, Davis CL. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 1996; 28: 561–571.
34. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55: 2457–2466.
35. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395–400.
36. Adeyi OA, Girnita AL, Howe J, et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005; 14: 53–62.
37. Hardy MA, Suciu-Foca N, Reed E, et al. Immunomodulation of kidney and heart transplants by anti-idiotypic antibodies. Ann Surg 1991; 214: 522–528; discussion 8-30.
38. Jackson AM, Kraus ES, Orandi BJ, Segev DL, Montgomery RA, Zachary AA. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int 2015; 87: 409–416.
39. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant 2014; 14: 59–69.
40. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405–2413.
41. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231–235.
42. Tillou X, Poirier N, Le Bas-Bernardet S, et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010; 78: 152–159.